1ISG-008 Cost efficacy analysis of abiraterone in newly diagnosed high risk metastatic castration sensitive prostate cancer. (24th March 2020)

• Record Type: Journal Article
• Authors: Soares, A; Alcobia, A
• Is Part Of: European journal of hospital pharmacy. Volume 27(2020)Supplement 1
• Page Start: A4
• Page End: A4
• Publication Date: 2020-03-24
• Subjects: Pharmacy -- Periodicals; Hospital pharmacies -- Periodicals; 615.1
• DOI: 10.1136/ejhpharm-2020-eahpconf.8
• Languages: English
• ISSNs: 2047-9956

Abstract

Abstract : Background and importance: Abiraterone was recently proved by the EMA for addition to androgen deprivation therapy (ADT), associated with prednisone (P), in metastatic castration sensitive prostate cancer. The economic impact could be important. Aim and objectives: The aim of this study was to evaluate the cost efficacy of abiraterone in newly diagnosed high risk metastatic castration sensitive prostate cancer. Material and methods: Abiraterone efficacy outcomes are based on the LATITUDE 1 2 trial. Treatment costs were calculated based on the direct costs of the drugs in 2019. This study was conducted from an institutional perspective—the hospital perspective. Results: Based on the LATITUDE trial, 1 2 the overall survival for the abiraterone+P+ADT group was 53.3 versus 36.5 months in the ADT group. Median treatment duration was 24 months for the abiraterone+P+ADT group and 14 months for the ADT group. Adding abiraterone+P to ADT resulted in a marginal efficacy of 1, 4 years compared with ADT alone. The marginal costs associated were 70.163€. The incremental cost efficacy ratio calculated for abiraterone+P was 50.116€. Conclusion and relevance: Based on this analysis, the incremental cost efficacy ratio calculated for abiraterone in metastatic castration sensitive prostate cancer setting was increased, considering the potential number of patients. With limited budgets, cost efficacy analyses are useful tools for the pharmacy and for decisions by therapeutics committees on drug selection. References and/or acknowledgements: 1. Fizazi K, et al. N Engl J Med 2017;377:352–60. 2. Fizazi K, et al. Lancet Oncol 2019;20:686–700. No conflict of interest.